A new study might show promise for cannabis becoming an effective therapeutic for chemotherapy patients. And a publicly listed company is behind it.
What’s happening:
- Tilray Brands (NASDAQ: TLRY) has announced new results from a study done through their subsidiary Tilray Medical which was focused on dosing chemotherapy patients experiencing constant vomiting with THC and CBD
By the numbers:
- 147 individual patients participated in the study which was conducted over the course of 6 years
- Each patient took 2.5 milligrams of THC and 2.5 milligrams of CBD in capsules which were administered multiple times a day
- Only 8% of patients who were dosed with a placebo experienced relief from vomiting, compared to 24% of patients who were dosed with THC and CBD
Why it matters:
- Cannabis continues to show enormous promise for different types of medical applications, which has even led large companies such as Philip Morris (NYSE: PM) to begin launching medical cannabis products in partnership with established cannabis operators
Going deeper:
- Tilray Medical supplies GMP certified medical cannabis to countries around the world and has also been accelerating scientific research around cannabis as a potential treatment for multiple health disorders, including epilepsy, PTSD and other health issues
The intrigue:
- Tilray Brands has even been expanding beyond cannabis lately, previously purchasing multiple craft breweries from Molson Coors (NYSE: TAP) in a new deal to make a big push into the alcoholic beverage business
